Morphosys Ag's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Morphosys Ag (MOR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Morphosys Ag vs Its Competitors
- TTM: Trailing 12-month revenue of 258M vs 713,998M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months), vs accelerating (+43.1%) for its tracked peer group.
- Growth: Morphosys Ag generated -14.4% revenue growth year over year in Q4 2023, vs 0.6% for its competitors combined.
- Profitability: Its -79.6% net margin compares with 13.8% for the peer group.
- Peer revenue share: Morphosys Ag accounted for 0.1% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.50M compares with $1.02M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MOR Sales vs. its Competitors, Q4 2023
Morphosys Ag reported revenue contraction of 14.37 % year on year in Q4 2023, below its competitors' combined revenue growth of 0.58 %.
With a net margin of -79.63 %, Morphosys Ag reported lower profitability than its competitors (13.81 %).
Morphosys Ag generated 0.10 % of the combined sales of its peer group, down from 0.12 % a year earlier.
API endpoints for this dataset
Morphosys Ag vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Morphosys Ag reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Morphosys Ag and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Morphosys Ag | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Morphosys Ag's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -14.4% for Morphosys Ag. Morphosys Ag's share of combined industry revenue moved from 0.06% to 0.05%, a loss of 0.01 percentage points.
Morphosys Ag's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Morphosys Ag | No | No | No | Yes |
| Competitors combined (185) | ||||
| High-Confidence Competitors (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MOR Stock Performance relative to its Competitors
MOR Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 4 | Gossamer Bio Inc | 282.9% | Outperformed |
| 5 | An2 Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Morphosys Ag's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Morphosys Ag's Comment on Competition and Industry Peers
Publicly Traded Peers of Morphosys Ag
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Morphosys Ag |
650.57 | 257.74 |
 Eli Lilly And Company |
1,291,177.42 | 86,462.00 |
 Akari Therapeutics Plc |
913,241.43 | - |
 Johnson and Johnson |
691,509.13 | 99,335.00 |
 Abbvie Inc |
526,142.24 | 66,014.00 |
 Merck and Co Inc |
364,300.30 | 66,569.00 |
| SUBTOTAL | 5,882,402.84 | 751,170.11 |
Sign in to see all competitors of Morphosys Ag.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Morphosys Ag versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Morphosys Ag's Competitors Named by the Company
Competitive relationships identified from Morphosys Ag reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Tradeup Acquisition Corp | Company report | 85% |
| Argenx Se | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Abcellera Biologics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Morphosys Ag's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Morphosys Ag's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Morphosys Ag's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Morphosys Ag | 651 | 504,377 | -401,621 |
| Eli Lilly And Company | 1,291,177 | 1,729,240 | 551,594 |
| Akari Therapeutics Plc | 913,241 | - | -4,674,667 |
| Johnson and Johnson | 691,509 | 705,504 | 114,311 |
| Abbvie Inc | 526,142 | 1,158,140 | 181,509 |
| Merck and Co Inc | 364,300 | 887,587 | 42,267 |
| PEERS TOTAL | 5,881,752 | 1,019,574 | 147,861 |
Morphosys Ag's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Morphosys Ag's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (447 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 78.19 % | 38.09 % (avg) | +40.1 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | -81.93 % | -6.73 % (avg) | -75.2 pp |
| Capital Intensity (Capex / Revenue) | 0.15 % | 7.49 % (avg) | -7.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Morphosys Ag's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | 4.6x | 4.2x | +0.4x |
| Return on Equity | -378.24 % | industry aggregate | -391.47 % |
| Return on Invested Capital | -13.42 % | -9.73 % (avg) | -3.69 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Morphosys Ag's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | -43.17 % | 37.95 % | -12.08 % |
| Operating Margin | - | -79.32 % | - |
| Return on Invested Capital | -21.11 % | -9.21 % | -13.42 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Morphosys Ag's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.15 % vs industry average 7.49 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Morphosys Ag's dedicated Suppliers and Customers pages, not here.
Morphosys Ag's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Morphosys Ag falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Morphosys Ag's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months).
Weaknesses
- Return on equity 391.5 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (53.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Morphosys Ag's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Morphosys Ag | 0.60 | 3.08 | 5.01 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Morphosys Ag's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Morphosys Ag | Q4 2023 | -12.1 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +11.9 % | +7.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Morphosys Ag's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Morphosys Ag | Q4 2023 | +30.3 % | -81.4 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Morphosys Ag's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Morphosys Ag | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Morphosys Ag's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Morphosys Ag | - | 2.52 |
| Eli Lilly And Company | 46.92 | 14.93 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 42.72 | 6.96 |
| Abbvie Inc | 51.10 | 7.97 |
| Merck and Co Inc | 118.94 | 5.47 |
| PEERS AVERAGE | 54.12 | 7.83 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.